Journal of the National Comprehensive Cancer Network

Papers
(The H4-Index of Journal of the National Comprehensive Cancer Network is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology704
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology578
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021568
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology513
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology513
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology502
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology472
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology433
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology431
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology362
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology329
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology324
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020285
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021277
Role of Immunotherapy in Triple-Negative Breast Cancer277
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020276
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal262
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020255
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology236
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology227
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology225
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020175
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology169
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021167
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021166
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021160
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022156
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021146
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology141
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021140
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology127
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology126
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology115
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology114
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021104
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022100
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology89
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology86
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.202185
NCCN Guidelines® Insights: Bladder Cancer, Version 2.202285
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.202176
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.202075
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology74
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology74
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.202273
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.202365
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.202062
NCCN Guidelines Insights: Survivorship, Version 2.202057
Safety at the Time of the COVID-19 Pandemic: How to Keep Our Oncology Patients and Healthcare Workers Safe57
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.202251
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology51
0.074226856231689